Filtered By:
Vaccination: Meningitis Vaccine
This page shows you your search results in order of date. This is page number 20.
Order by Relevance | Date
Total 2891 results found since Jan 2013.
Secondary Cases of Invasive Disease Caused by Encapsulated and Nontypeable Haemophilus influenzae - 10 U.S. Jurisdictions, 2011-2018
MMWR Morb Mortal Wkly Rep. 2023 Apr 14;72(15):386-390. doi: 10.15585/mmwr.mm7215a2.ABSTRACTHaemophilus influenzae (Hi) can cause meningitis and other serious invasive disease. Encapsulated Hi is classified into six serotypes (a-f) based on chemical composition of the polysaccharide capsule; unencapsulated strains are termed nontypeable Hi (NTHi). Hi serotype b (Hib) was the most common cause of bacterial meningitis in children in the pre-Hib vaccine era, and secondary transmission of Hi among children (e.g., to household contacts and in child care facilities) (1,2) led to the Advisory Committee on Immunization Practices (A...
Source: MMWR Morb Mortal Wkl... - April 13, 2023 Category: Epidemiology Authors: Sara E Oliver Amy B Rubis Heidi M Soeters Arthur Reingold Meghan Barnes Susan Petit Ashley E Moore Lee H Harrison Ruth Lynfield Kathy M Angeles Kari E Burzlaff Ann Thomas William Schaffner Henju Marjuki Xin Wang Susan Hariri Source Type: research
Pneumococcal carriage following PCV13 delivered as one primary and one booster dose (1 + 1) compared to two primary doses and a booster (2 + 1) in UK infants
Vaccine. 2023 Apr 10:S0264-410X(23)00400-0. doi: 10.1016/j.vaccine.2023.04.017. Online ahead of print.ABSTRACTIn January 2020 the UK changed from a 2 + 1 schedule for 13-valent pneumococcal conjugate vaccine (PCV13) to a 1 + 1 schedule (doses at 3 and 12 months) based on a randomized immunogenicity trial comparing the two schedules. Carriage prevalence measured at the time of booster and 6 months later in 191 of the 213 study infants was 57 % (109/191) and 60 % (114/190) respectively. There were eight episodes of vaccine-type (VT) or vaccine-related 6C carriage in the 2 + 1 and six in the 1 + 1 group; ≥4-fold rises in se...
Source: Vaccine - April 12, 2023 Category: Allergy & Immunology Authors: David Goldblatt Nick J Andrews Carmen L Sheppard Samuel Rose Parvinder K Aley Lucy Roalfe Jo Southern Hannah Robinson Emma Pearce Emma Plested Marina Johnson David J Litt Norman K Fry Pauline Waight Matthew D Snape Elizabeth Miller Source Type: research
Effect of reduced two-dose (1+1) schedule of 10 and 13-valent pneumococcal conjugate vaccines (Synflorix < sup > TM < /sup > and Prevenar13 < sup > TM) < /sup > ) on nasopharyngeal carriage and serotype-specific immune response in the first two years of life: Results from an open-labelled randomized controlled trial in Indian children
CONCLUSION: The reduced dose schedule (1 + 1) of PCV13 results in significant VT-carriage reduction in the second year of life. Immune protection provided by 1 + 1 schedules of PCV10 and PCV13 in the second year of life is comparable to WHO-recommended 3-dose schedules.PMID:37045679 | DOI:10.1016/j.vaccine.2023.04.008
Source: Vaccine - April 12, 2023 Category: Allergy & Immunology Authors: Anand Kawade Girish Dayma Aditi Apte Nilima Telang Meenakshi Satpute Emma Pearce Lucy Roalfe Rakesh Patil Yanyun Wang Navideh Noori Arun Gondhali Sanjay Juvekar Assaf P Oron Sonali Sanghavi David Goldblatt Ron Dagan Ashish Bavdekar Source Type: research
Vaccine co-administration in adults: An effective way to improve vaccination coverage
Hum Vaccin Immunother. 2023 Apr 11:2195786. doi: 10.1080/21645515.2023.2195786. Online ahead of print.ABSTRACTThe ongoing COVID-19 pandemic highlights that complications and mortality associated with infectious diseases increase with age. Various vaccines are recommended for adults, but coverage rates remain suboptimal. Although co-administration would improve vaccine uptake and timely immunization, this is not routine practice in adults. We review key data on co-administration of vaccines in children and adults to reassure healthcare providers about its safety and advantages. In European countries and the United States, c...
Source: Herpes - April 11, 2023 Category: Infectious Diseases Authors: Paolo Bonanni Robert Steffen J örg Schelling Lina Balaisyte-Jazone Inga Posiuniene Maciej Zato ński Pierre Van Damme Source Type: research
Immunoglobulin profiling with large high-density peptide microarrays as screening method to detect candidate proteins for future biomarker detection in dogs with steroid-responsive meningitis-arteritis
Discussion. IL1Ra is an anti-inflammatory acute phase protein. Different immunoglobulin binding patterns on IL1Ra could be involved in the pathogenesis of SRMA and IL1Ra might be developed as future biomarker for SRMA.
Source: PLoS One - April 10, 2023 Category: Biomedical Science Authors: Jasmin Nicole Nessler Source Type: research
A systematic review of pneumococcal conjugate vaccine impact on pneumococcal nasopharyngeal colonisation density in children under 5 years of age
CONCLUSION: There was no consensus regarding the impact of PCV on pneumococcal nasopharyngeal density. We recommend the use of standardised methods to evaluate PCV impact on density.PMID:37032228 | DOI:10.1016/j.vaccine.2023.03.063
Source: Vaccine - April 9, 2023 Category: Allergy & Immunology Authors: Isatou Jagne Claire von Mollendorf Ashleigh Wee-Hee Belinda Ortika Catherine Satzke Fiona M Russell Source Type: research
Reduced quantity and function of pneumococcal antibodies are associated with exacerbations of COPD in SPIROMICS
Clin Immunol. 2023 Apr 6:109324. doi: 10.1016/j.clim.2023.109324. Online ahead of print.ABSTRACTWhile hypogammaglobulinemia is associated with COPD exacerbations, it is unknown whether frequent exacerbators have specific defects in antibody production/function. We hypothesized that reduced quantity/function of serum pneumococcal antibodies correlate with exacerbation risk in the SPIROMICS cohort. We measured total pneumococcal IgG in n = 764 previously vaccinated participants with COPD. In a propensity-matched subset of n = 200 with vaccination within five years (n = 50 without exacerbations in the previous year; n = 75 wi...
Source: Clinical Immunology - April 8, 2023 Category: Allergy & Immunology Authors: David C LaFon Han Woo Neal Fedarko Antoine Azar Harry Hill Anne E Tebo Thomas B Martins MeiLan K Han Jerry A Krishnan Victor E Ortega Igor Barjaktarevic Robert J Kaner Annette Hastie Wanda K O'Neal David Couper Prescott G Woodruff Jeffrey L Curtis Nadia N Source Type: research
